Employees: NN (None)Legal category: 5470Size: PMECreation date: 2021-05-11 (4 years)Status: ActiveBusiness sector: Fonds de placement et entités financières similairesLocation: THEZAN-LES-BEZIERS (34490), Herault
Les données financières de cette entreprise sont partiellement disponibles (liasse simplifiée ou données confidentielles). Certaines sections ne sont pas affichées.
TR PHARMACIE : revenue, balance sheet and financial ratios
TR PHARMACIE is a French company
founded 4 years ago,
specialized in the sector Fonds de placement et entités financières similaires.
Based in THEZAN-LES-BEZIERS (34490),
this company of category PME
shows in 2024 a net income positive of 4 k€.
Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Financial history - TR PHARMACIE (SIREN 899408611)
Indicator
2024
2023
2022
2021
Revenue
N/C
N/C
N/C
N/C
Net income
4 440 €
4 472 €
-21 604 €
8 216 €
EBITDA
-492 €
-169 €
-33 527 €
-5 785 €
Net margin
N/C
N/C
N/C
N/C
Revenue and income statement
In 2024, TR PHARMACIE generates positive net income of 4 k€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax. Change over 2021-2024: 8 k€ -> 4 k€.
EBITDA (2024)
?
Gross Operating Surplus (EBITDA)
Definition
Resources generated by current operations, before depreciation and financial expenses.
Formula
Value added - Personnel expenses - Taxes
Interpretation
Positive = profitable activity
-492 €
EBIT (2024)
?
EBIT (Operating Income)
Definition
Operating income, including depreciation and provisions.
Formula
EBITDA - Depreciation and provisions + Reversals
-492 €
Net income (2024)
?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax
4 440 €
Loading income statement...
Income statement
Item
Amount
% Revenue
Change
The detailed income statement is not available for this company (simplified accounts or confidential data).
Chart evolution
Show :
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Assets
Loading data...
Item
Gross
Deprec.
Net
%
Change
Assets balance sheet data not available for this company
Liabilities
Loading data...
Item
Year
%
Change
Liabilities balance sheet data not available for this company
Solvency and debt ratios
The debt ratio (= Financial debt / Equity x 100) stands at 133%. Debt level is high: negotiating margin with banks is reduced. Financial autonomy (= Equity / Total assets x 100) reaches 43%. This high autonomy means the company finances most of its assets through equity, a sign of strength. Debt repayment capacity (= Financial debt / Cash flow) indicates it would take 97.2 years of cash flow to repay all financial debt. Beyond 7 years, banks generally consider credit risk as high.
Debt ratio (2024)
?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low 50-100% : Moderate > 100% : High
132.541%
Financial autonomy (2024)
?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy 20-30% : Average < 20% : Low
43.003%
Repayment capacity (2024)
?
Repayment capacity
Definition
Number of years needed to repay debts with cash flow.
Formula
Financial debt / Cash flow
Interpretation
< 3 years : Excellent 3-5 years : Fair > 5 years : Warning
97.174
Solvency indicators evolution TR PHARMACIE
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Indicator
2021
2022
2023
2024
Debt ratio
0.0
134.179
133.387
132.541
Financial autonomy
100.0
42.702
42.847
43.003
Repayment capacity
0.0
-19.664
95.77
97.174
Cash flow / Revenue
None%
None%
None%
None%
Sector positioning
Debt ratio
132.542024
2022
2023
2024
Q1: 0.01
Med: 13.69
Q3: 116.56
Average
In 2024, the debt ratio of TR PHARMACIE (132.54) ranks above the median of the sector. This ratio measures the weight of debt relative to equity. A reduction effort could improve financial strength.
Financial autonomy
43.0%2024
2022
2023
2024
Q1: 13.95%
Med: 55.8%
Q3: 90.35%
Average
In 2024, the financial autonomy of TR PHARMACIE (43.0%) ranks below the median of the sector. This ratio represents the share of equity in total financing. An improvement would strengthen the competitive position.
Repayment capacity
97.17 years2024
2022
2023
2024
Q1: 0.0 years
Med: 0.15 years
Q3: 4.69 years
Average+50 pts over 3 years
In 2024, the repayment capacity of TR PHARMACIE (97.17) ranks above the median of the sector. This ratio indicates the number of years needed to repay debt with cash flow. A reduction effort could improve financial strength.
Liquidity ratios
Interest coverage (2024)
?
Interest coverage
Definition
Ability to cover interest charges with operating income.
Formula
EBIT / Interest expenses
Interpretation
> 3 : Comfortable 1.5-3 : Acceptable < 1.5 : Risk
-623.374
Liquidity indicators evolution TR PHARMACIE
Visualisation créée via abddaf.fr Sources : INPI & BCE - Retraitements : Ministère de l'économie
Indicator
2021
2022
2023
2024
Liquidity ratio
None
None
None
None
Interest coverage
0.0
-6.195
-1988.166
-623.374
Sector positioning
Interest coverage
-623.37x2024
2022
2023
2024
Q1: -144.56x
Med: -8.16x
Q3: 0.0x
Average-23 pts over 3 years
In 2024, the interest coverage of TR PHARMACIE (-623.4x) ranks below the median of the sector. This ratio indicates how many times operating income covers interest expenses. An improvement would strengthen the competitive position.
Positioning of TR PHARMACIE in its sector
Comparison with sector Fonds de placement et entités financières similaires
Valuation estimate
Indicative estimate only : the number of comparable transactions in this sector is limited (26 transactions).
This range of 12 470€ to 86 040€ is provided for information purposes only and requires in-depth analysis to be confirmed.
Estimated enterprise value2024
Indicative
12k€57k€86k€
57 621 €Range: 12 470€ - 86 040€
NAF 5 année 2024
Valuation evolution
Visualisation creee via abddaf.fr Sources : BODACC & INPI
How is this estimate calculated?
This estimate is based on the analysis of 26 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
Net Income Multiple: Relevant for mature companies with stable results.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Similar companies (Fonds de placement et entités financières similaires)
Compare TR PHARMACIE with other companies in the same sector:
The revenue of TR PHARMACIE is not publicly disclosed (confidential accounts filed with INPI).
Is TR PHARMACIE profitable?
Yes, TR PHARMACIE generated a net profit of 4 k€ in 2024.
Where is the headquarters of TR PHARMACIE ?
The headquarters of TR PHARMACIE is located in THEZAN-LES-BEZIERS (34490), in the department Herault.
Where to find the tax return of TR PHARMACIE ?
The tax return of TR PHARMACIE is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
In which sector does TR PHARMACIE operate?
TR PHARMACIE operates in the sector Fonds de placement et entités financières similaires (NAF code 64.30Z). See the 'Sector positioning' section above to compare the company with its competitors.
Item evolution
Rotate your phone to landscape mode to view the chart